Evidence map›Paper›PMID 35071687›Full record

ArticleOpen forum infectious diseases2022

Estimates of Presumed Population Immunity to SARS-CoV-2 by State in the United States, August 2021.

Marie C D Stoner, Frederick J Angulo, Sarah Rhea, Linda Morris Brown, Jessica E Atwell, Jennifer L Nguyen, John M McLaughlin, David L Swerdlow, Pia D M MacDonald

Abstract read
In one paragraph

Article in Open forum infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Marie C D StonerRTI International, Research Triangle Park, North Carolina, USA.ORCID https://orcid.org/0000-0002-7189-8669
Frederick J AnguloMedical Development, Scientific, and Clinical Affairs, Pfizer Vaccines, Pfizer Inc., Collegeville, Pennsylvania, USA.
Sarah RheaRTI International, Research Triangle Park, North Carolina, USA.
Linda Morris BrownRTI International, Research Triangle Park, North Carolina, USA.
Jessica E AtwellMedical Development, Scientific, and Clinical Affairs, Pfizer Vaccines, Pfizer Inc., Collegeville, Pennsylvania, USA.
Jennifer L NguyenMedical Development, Scientific, and Clinical Affairs, Pfizer Vaccines, Pfizer Inc., Collegeville, Pennsylvania, USA.
John M McLaughlinMedical Development, Scientific, and Clinical Affairs, Pfizer Vaccines, Pfizer Inc., Collegeville, Pennsylvania, USA.
David L SwerdlowMedical Development, Scientific, and Clinical Affairs, Pfizer Vaccines, Pfizer Inc., Collegeville, Pennsylvania, USA.
Pia D M MacDonaldRTI International, Research Triangle Park, North Carolina, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInformation is needed to monitor progress toward a level of population immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) sufficient to disrupt viral transmission. We estimated the percentage of the US population with presumed immunity to SARS-CoV-2 due to vaccination, natural infection, or both as of August 26, 2021.

methodsPublicly available data as of August 26, 2021, from the Centers for Disease Control and Prevention were used to calculate presumed population immunity by state. Seroprevalence data were used to estimate the percentage of the population previously infected with SARS-CoV-2, with adjustments for underreporting. Vaccination coverage data for both fully and partially vaccinated persons were used to calculate presumed immunity from vaccination. Finally, we estimated the percentage of the total population in each state with presumed immunity to SARS-CoV-2, with a sensitivity analysis to account for waning immunity, and compared these estimates with a range of population immunity thresholds.

resultsIn our main analysis, which was the most optimistic scenario, presumed population immunity varied among states (43.1% to 70.6%), with 19 states with ≤60% of their population having been infected or vaccinated. Four states had presumed immunity greater than thresholds estimated to be sufficient to disrupt transmission of less infectious variants (67%), and none were greater than the threshold estimated for more infectious variants (≥78%).

conclusionsThe United States remains a distance below the threshold sufficient to disrupt viral transmission, with some states remarkably low. As more infectious variants emerge, it is critical that vaccination efforts intensify across all states and ages for which the vaccines are approved.

Indexed as

COVID-19 vaccinationpopulation immunitySARS-CoV-2

Identifiers

PMID35071687
PMCPMC8774091

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.